| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22004 |
| Drug |
Amivantamab |
| Brand |
Rybrevant® |
| Indication |
For the treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy. |
| Rapid review commissioned |
17/01/2022 |
| Rapid review completed |
03/02/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
23/02/2022 |
| Pre-submission consultation with Applicant |
28/03/2022 |
| Full submission received from Applicant |
30/08/2022 |
| Preliminary review sent to Applicant |
24/01/2023 |
| NCPE assessment re-commenced |
22/02/2023 |
